Lipid 01-1 is an ionizable lipid investigated for lipid nanoparticle delivery of mRNA encoding a CD19/CD3 bispecific T-cell engager. In WO2024131874A1, 01-1-based LNPs supported serum antibody expression and were used in a Nalm6 leukemia model with human PBMCs. A single intravenous dose of mRNA1-LNPs reduced tumor bioluminescence relative to controls and the recombinant antibody regimen tested. Its structure combines a hydroxyl-bearing diamine headgroup, a cyclobutyl substituent and two ester-linked branched hydrophobic groups.

Lipid 03-135 is an ionizable lipid investigated for lipid nanoparticle delivery of mRNA encoding a CD19/CD3 bispecific T-cell engager developed by Abogen. In WO2024131874A1, its formulation showed the highest plotted serum antibody concentrations at 24 and 48 hours among five tested lipids after a single intravenous dose of mRNA1 in NOD/SCID mice.